Welcome to our dedicated page for ALT5 Sigma Corporation news (Ticker: ALTS), a resource for investors and traders seeking the latest updates and insights on ALT5 Sigma Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALT5 Sigma Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALT5 Sigma Corporation's position in the market.
ALT5 Sigma (NASDAQ:ALTS) announced the approval of all proposed resolutions at its 2024 AGM, including the re-election of board members and the election of CEO Peter Tassiopoulos to the Board. The company reported achieving record transaction volumes exceeding US$2 billion in 2024 through its ALT5 Pay and Prime platforms.
The company plans to spin-off its healthcare assets into Alyea Therapeutics in the first half of 2025. Alyea has executed a non-binding LOI to acquire Soin Bioscience , which would bring innovative clear patch pain medication technology to its portfolio. The global pain patch market is projected to grow from US$4.80 billion in 2021 to US$7.33 billion by 2031.
ALT5 Sigma (NASDAQ:ALTS) reported strong Q3 2024 financial results with record revenue of $4.94 million and gross profit of $2.39 million in its fintech segment. The company achieved a fintech net income of $714k and Adjusted EBITDA of $889k. Cash and equivalents stood at $8.67 million. The company plans to separate its biotech business, Alyea Therapeutics, in the first half of 2025, with intentions to finance Alyea's operations separately. Transaction volume exceeded $600 million for Q3. The company recently acquired additional IP to enhance features planned for Q4 and fiscal 2025.
ALT5 Sigma (NASDAQ:ALTS) has appointed Ron Pitters to its Board of Directors. Pitters, currently serving as CAO of Axos Clearing and President of Axos Business Center Corp., brings over 20 years of experience in fintech, financial services, and emerging technologies. His global business management experience spans Asia, the Middle East, Europe, and the USA.
ALT5 Sigma, a fintech innovator providing blockchain-powered technologies, processed over US$1.2 billion in cryptocurrency transactions in 2023 through its platforms ALT5 Pay and ALT5 Prime. The company is also developing innovative solutions for the opioid crisis through its biotech division.
ALT5 Sigma (NASDAQ:ALTS) announces its participation in Spartan Capital Securities' inaugural investor conference scheduled for November 4th at the Pierre Hotel in New York. The event will feature presentations from over 30 selected companies, including panel discussions, one-on-one meetings, and networking sessions. The conference, organized in partnership with B2i Digital, aims to facilitate interactions between companies and Spartan Capital's investor base. ALT5's CRO Vay Tham will present the company's growth strategy and market position to key capital market influencers.
ALT5 Sigma (NASDAQ:ALTS) announced its participation in the upcoming Money20/20 Las Vegas conference from October 27-30, 2024. The company will exhibit at booth #11713 at The Venetian Resort, providing product demonstrations and solutions to over 12,000 attendees. Money20/20 USA is the largest gathering of the global money ecosystem, including banks, payments, tech, startups, and fintech. ALT5 Sigma's CRO Vay Tham highlighted the company's growing volumes in crypto payments, positioning them as an innovator in the payments ecosystem.
ALT5 Sigma (NASDAQ:ALTS) reported a record transaction volume of over $240 million for September 2024, representing a 151% year-over-year increase from September 2023. The company's year-to-date transaction volume reached approximately $1.5 billion, with Q3 exceeding $600 million, marking a record quarter. ALT5 Sigma, a fintech company providing blockchain-powered technologies for digital asset services, attributes this growth to realigned sales and marketing efforts, global tradeshow presence, new customer onboardings, and increased flows from existing customers.
The company offers two main platforms: ALT5 Pay, a cryptocurrency payment gateway, and ALT5 Prime, an electronic over-the-counter trading platform for digital assets. In 2023, ALT5 Sigma processed over $1.2 billion in cryptocurrency transactions. The company is also involved in biotech activities, focusing on developing innovative solutions to address the opioid crisis.
ALT5 Sigma (NASDAQ:ALTS) has announced a strategic plan to separate into two independent publicly traded companies. The separation will result in ALT5 continuing as a leading fintech organization, while the Biotech segment will become Alyea Therapeutics , focusing on non-addictive pain management therapies.
Key benefits of the separation include:
- Increased focus and agility within respective industries
- Tailored capital allocation strategies
- Enhanced strategic flexibility for M&A
- Unique investment profiles for diverse investor bases
- Distinct boards and management teams
ALT5 will maintain its focus on blockchain-powered technologies, offering ALT5 Pay and ALT5 Prime platforms. Alyea Therapeutics will develop non-addictive pain management therapies, with its lead candidate JAN123 receiving FDA orphan drug designation.
ALT5 Sigma (NASDAQ:ALTS), a fintech company specializing in blockchain-powered technologies for digital asset management, has reported impressive growth in its transaction volume. For August 2024, the company's transaction volume reached US$192 million, marking a 120% year-over-year increase from August 2023's $87 million. The year-to-date transaction volume for the first eight months of 2024 stands at US$1.250 billion, representing a 104% year-over-year increase. This substantial growth demonstrates ALT5's strong performance in the digital asset space and its ability to capitalize on the increasing demand for blockchain-based financial solutions.
ALT5 Sigma (NASDAQ:ALTS), a fintech company specializing in blockchain-powered technologies for digital asset management, has announced its participation in the upcoming iFX Bangkok Expo. The event, scheduled for September 16-18, 2024, will be held at the Centra Grand & Bangkok Convention Centre. ALT5 will be exhibiting at booth #88 throughout the three-day show, offering product demonstrations and information to over 4,500 attendees.
Vay Tham, CRO of ALT5 Sigma, emphasized the importance of iFX Expo Asia as the leading online trading event and an excellent platform to showcase ALT5 Prime, their electronic over-the-counter trading platform for digital assets. The company's participation aligns with its global expansion plans and efforts to grow its customer base worldwide.
ALT5 Sigma (NASDAQ:ALTS), a fintech leader in blockchain-powered digital asset management, has appointed Peter Tassiopoulos as Chief Executive Officer. Tony Issac will transition to President while remaining Chairman of the Board. Tassiopoulos brings over 30 years of leadership experience in healthcare, finance, and technology sectors.
In his new role, Tassiopoulos will guide ALT5 Sigma's strategic vision, oversee healthcare business restructuring, and drive growth in the digital asset marketplace. His experience includes completing over $1 billion in M&A, divestitures, and financing transactions. The company is exploring options to enhance stockholder value through potential strategic realignment and expansion of digital marketplace offerings.
As an inducement, Tassiopoulos was granted 400,000 restricted stock units (RSUs) that vest immediately, subject to the terms of ALT5's 2023 Equity Incentive Plan.
FAQ
What is the current stock price of ALT5 Sigma Corporation (ALTS)?
What is the market cap of ALT5 Sigma Corporation (ALTS)?
